Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [6][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.27% from August 22 to September 4, 2025, which is approximately 3.07 percentage points lower than the index [13][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and chemical preparation sectors showing the highest gains of 12.17% and 5.45%, respectively. In contrast, the in vitro diagnostics and raw materials sectors experienced declines of 5.96% and 4.95% [16][19]. - Approximately 22% of stocks in the industry recorded positive returns, while around 78% experienced negative returns during the reporting period [17][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 55.41 times, with a relative PE ratio of 4.23 times compared to the CSI 300 index, indicating little change in industry valuation [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.27% from August 22 to September 4, 2025 [13]. - Most sub-sectors recorded negative returns, with medical research outsourcing and chemical preparations leading in gains [16]. - About 22% of stocks in the industry had positive returns, while 78% had negative returns [17]. 2. Industry News - The National Healthcare Security Administration announced the list of drugs for the 2025 National Basic Medical Insurance, with 718 submissions and 535 passing the initial review [27]. - The report highlights the upcoming national medical insurance negotiations and the analysis of 25 traditional Chinese medicine products [27]. 3. Company Announcements - Guangzhou Baiyunshan Pharmaceutical Group announced that its subsidiary received approval for a drug to pass the consistency evaluation for generic drugs [28]. 4. Industry Outlook - The report suggests focusing on investment opportunities in the innovative drug sector and related areas, including medical devices and traditional Chinese medicine [29][32].

Core Viewpoint - Tongce Medical (600763) shows a mixed performance in terms of stock price and fund flow, with a slight increase in stock price but significant net outflow of main funds on August 29, 2025 [1][2]. Fund Flow Summary - On August 29, 2025, the stock closed at 47.14 yuan, up 1.77%, with a turnover rate of 4.04% and a trading volume of 180,600 lots, amounting to a total transaction value of 854 million yuan [1]. - The fund flow data indicates a net outflow of main funds amounting to 35.41 million yuan, accounting for 4.15% of the total transaction value, while retail investors saw a net inflow of 18.27 million yuan, representing 2.14% of the total [1][2]. Recent Fund Flow Overview - The recent five-day fund flow shows a trend of net outflows from main funds, with the most significant outflow occurring on August 27, 2025, at 95.11 million yuan, while retail investors consistently showed net inflows [2]. Company Performance Metrics - As of the latest report, Tongce Medical has a total market value of 21.085 billion yuan, with a net asset value of 4.467 billion yuan and a net profit of 321 million yuan [3]. - The company reported a year-on-year increase in main revenue of 2.68% to 1.448 billion yuan and a net profit increase of 3.67% to 321 million yuan for the first half of 2025 [3]. - The second quarter of 2025 showed a slight increase in main revenue to 704 million yuan, with a net profit of 137 million yuan, reflecting a year-on-year increase of 0.44% [3]. Industry Comparison - Tongce Medical's price-to-earnings ratio (P/E) stands at 32.83, significantly lower than the industry average of 84.92, indicating a favorable valuation compared to peers [3]. - The company's gross margin is 40.75%, higher than the industry average of 35.7%, and its net margin of 26.26% is substantially above the industry average of 3.53% [3]. Analyst Ratings - Over the past 90 days, six institutions have rated the stock, with four buy ratings and two hold ratings, and the average target price set at 50.19 yuan [4].

Group 1 - The core viewpoint of the report is that Tongce Medical (600763.SH) is rated as a "buy" due to expected stable growth in performance and improved profitability in the first half of 2025 [1] - The orthodontics business is showing signs of recovery, with the number of dental chairs exceeding 3,100 [1] - The company is implementing a "three-three system" model to drive development, although the business of the three major hospitals has seen a decline [1]

Investment Rating - The investment rating for Tongce Medical (600763.SH) is "Buy" (maintained) [1] Core Views - In the first half of 2025, the company achieved steady revenue growth with a total revenue of 1.448 billion yuan, representing a year-on-year increase of 2.68%. The net profit attributable to the parent company was 321 million yuan, up 3.67% year-on-year [4][5] - The orthodontic business showed signs of recovery, generating revenue of 229 million yuan, an increase of 7.75% year-on-year. The company has a total of over 3,100 dental chairs across its medical institutions [5][6] - The company has adjusted its earnings forecast for 2025-2026 due to the impact of new hospital depreciation, now expecting net profits of 559 million yuan and 610 million yuan for 2025 and 2026, respectively [4][5] Financial Summary - For the first half of 2025, the company reported a gross margin of 40.75% and a net margin of 26.26%, with outpatient visits reaching 1.7322 million, a 1.21% increase year-on-year [4][5] - The company operates 89 medical institutions and employs 4,452 medical professionals, with a medical space exceeding 260,000 square meters [5] - The three major hospitals under the company experienced a revenue decline of 8.67% to 497 million yuan in the first half of 2025 [6] Earnings Forecast - The earnings forecast for 2025-2027 is as follows: net profit attributable to the parent company is expected to be 559 million yuan in 2025, 610 million yuan in 2026, and 702 million yuan in 2027, with corresponding P/E ratios of 37.4, 34.2, and 29.7 times [4][7]

Group 1 - The company announced the acquisition of 100% equity of Shanghai Cunj Medical Clinic Co., Ltd. for a total consideration of RMB 46 million, which includes a cash payment of RMB 15 million and the assumption of debts amounting to RMB 31 million [3][4] - The acquisition is part of the company's strategy to enter the Shanghai market, leveraging its established operational system and professional team in Zhejiang province, thus avoiding potential competition with existing operations [2][3] - The Shanghai Cunj Medical Clinic has not commenced substantial operations since its establishment, ensuring no competition with the listed company, and will be integrated into the company's unified management system post-acquisition [2][3] Group 2 - The project is currently in the fire safety acceptance application stage, and the company plans to expedite the application for the medical institution practice license to initiate trial operations as soon as possible [4] - The total investment for the project includes expenditures for renovation of RMB 37.09 million, project preparation costs of RMB 590,000, and equipment purchases of RMB 8.32 million [3]

Investment Rating - The report maintains a "Recommended" rating for the company [1][8] Core Views - The orthodontic business has stabilized and is showing renewed growth momentum, with a revenue of 2.29 billion yuan in H1 2025, representing a year-on-year increase of 7.75% [4][8] - The company reported a total revenue of 14.48 billion yuan in H1 2025, a 2.68% increase year-on-year, and a net profit of 3.21 billion yuan, up 3.67% year-on-year [4][8] - The overall business is recovering, with key financial indicators showing a trend of recovery growth [8] Financial Summary - For 2025, the company expects net profits of 5.26 billion yuan, 5.92 billion yuan, and 6.65 billion yuan for the years 2025, 2026, and 2027 respectively [8] - The company's gross margin for H1 2025 was 40.75%, while the net margin was 26.26%, indicating an improvement in profitability [8] - The company has a total market capitalization of 211 billion yuan and a total asset value of 6,182 million yuan [7][10] - The projected revenue for 2025 is 3.18 billion yuan, with a year-on-year growth rate of 10.8% [6][11] - The company’s earnings per share (EPS) for 2025 is estimated at 1.18 yuan, with a price-to-earnings (P/E) ratio of 40.1 [6][11]

Group 1 - The core point of the announcement is the acquisition of 100% equity of Shanghai Cunjing Dental Clinic by Tongce Medical, which aims to enhance its operational capabilities in the dental healthcare sector [1][2]. - The acquisition price totals RMB 46 million, which includes RMB 15 million for the equity transfer and RMB 31 million for the assumption of the original shareholders' debt [2][3]. - The project is currently in the fire safety acceptance application stage, and the company plans to expedite the application for the medical institution practice license after obtaining the acceptance document [3]. Group 2 - The acquisition is part of the company's strategic move to enter the Shanghai market, leveraging its established dental medical operation system and professional team in Zhejiang Province [2]. - The Shanghai Cunjing Dental Clinic has not engaged in substantial operations since its establishment, thus avoiding any competition with the listed company [2]. - The total investment of RMB 46 million includes expenditures for renovation, project preparation, and equipment purchases, with significant allocations for property renovation and decoration [3].

证券代码：600763 证券简称：通策医疗 编号：临 2025-025 二、交易价格 本次收购标的的交易总对价为人民币 4600 万元，该对价系基于目标公司的 通策医疗股份有限公司 关于收购上海存济口腔门诊部有限公司 100%股权 暨关联交易的补充公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"或"通策医疗"）于 2025 年 8 月 23 日披露了《关于收购上海存济口腔门诊部有限公司 100%股权暨关联交易的 公告》（公告编号：临 2025-024）。为进一步增进投资者对本次交易的理解， 现就相关事项补充说明如下： 一、项目背景 1、为有效控制项目投资风险，公司针对体系外大型口腔医院项目的投资建 设，采用由通策集团先行投资建设、后委托上市公司运营管理的轻资产运营模式。 公司曾于 2016 年 11 月 16 日与诸暨通策口腔医疗投资基金合伙企业（有限合伙） 签署《委托管理协议》，将后者所投资的武汉存济口腔医院、西安存济口腔医院 等大型口腔医院的经营权与管理权全面委托公司统一行 ...

Core Insights - The company reported a revenue of 1.448 billion yuan for the first half of 2025, representing a year-on-year increase of 2.68%, with a net profit attributable to shareholders of 321 million yuan, up 3.66% year-on-year, and a non-recurring net profit of 317 million yuan, up 3.85% year-on-year, which aligns with expectations [1] Development Trends - The outpatient volume continues to grow steadily, with the company reinforcing its clinic layout in Zhejiang Province. As of August 2025, the company operates 89 medical institutions and has 3,100 dental chairs. In the first half of 2025, the dental outpatient volume reached 1.7322 million visits, an increase of 1.21% year-on-year [2] - The company employs a "regional general hospital + branch" structure to standardize parts of the diagnosis and treatment process, which is expected to reduce the marginal customer acquisition costs for expanding the branch network. The "Dandelion Plan" aims to deepen penetration within the province, establishing a scalable growth engine [2] - The gross profit margin for the first half of 2025 was 40.75%, and the net profit margin was 26.26%, remaining stable overall. Each business line showed positive growth, with implant revenue at 255 million yuan (up 0.02%), orthodontics at 229 million yuan (up 7.75%), restoration at 230 million yuan (up 3.59%), and comprehensive services at 394 million yuan (up 2.44%) [2] - The company sees significant potential in pediatric dental services, which may become a new growth engine in the future [2] AI Technology and Service Innovation - The company is leveraging its self-developed MindHub AI platform to provide intelligent support across various scenarios, including clinical diagnosis, patient services, and operational management. This positions the company to build structural competitive barriers through top-tier medical resource aggregation, platform scale effects, and technology-driven innovation [3] - In 2025, the company will deepen its "medical + technology" dual-wheel strategy, accelerating penetration in both high-end markets and lower-tier markets to maintain its industry leadership [3] - The company plans to acquire 100% of Shanghai Cunjing Dental Clinic, which is expected to enhance its brand presence and recognition in the high-end market [3] Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 549 million yuan and 580 million yuan, reflecting year-on-year growth of 9.6% and 5.6%, respectively. The current stock price corresponds to a price-to-earnings ratio of 38.4 times for 2025 and 36.3 times for 2026 [4] - The company maintains an outperform rating and a target price of 53.2 yuan based on discounted cash flow (DCF) analysis, which corresponds to a price-to-earnings ratio of 43.3 times for 2025 and 41.0 times for 2026, indicating a potential upside of 12.9% from the current stock price [4]

Group 1 - The stock price of Tongce Medical reached 47.14 yuan as of August 25, 2025, with an increase of 0.86% from the previous trading day, and a trading volume of 170,555 lots, amounting to 800.2 million yuan [1] - Tongce Medical focuses on oral medical services and operates under a "regional general hospital + branch" model, with 44 branches established in Zhejiang Province and a total of 89 medical institutions as of the first half of 2025, employing 4,452 medical professionals and operating over 3,100 dental chairs [1] - On August 22, the company announced the acquisition of 100% equity in Shanghai Cunjie Dental Clinic for 46 million yuan, which is positioned for mid-to-high-end membership services, focusing on pediatric dentistry, implants, and comprehensive departments [1] - This acquisition marks the second merger and acquisition transaction completed by the company in 2025, following the purchase of Hangzhou Haiyin Kechuang Co., Ltd. for 55.4136 million yuan in April [1] - On August 23, the company hosted a research meeting with several institutions, including Northeast Securities and Huatai Securities, revealing that in the first half of 2025, it achieved operating revenue of 1.448 billion yuan, a year-on-year increase of 2.68%, and the number of outpatient visits reached 1.7322 million, up 1.21% year-on-year [1]